Spis treści:
Spis załączników:
Current_report_99_buy_back_espi.pdf (REPORT)
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
Current_report_99_buy_back_espi.pdf (REPORT)
| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
| UNI - EN REPORT No | 99 | / | 2019 | ||||||||
| Date of issue: | 2019-12-20 | ||||||||||
| Short name of the issuer | |||||||||||
| SOPHARMA AD | |||||||||||
| Subject | |||||||||||
| Notification for acquisition of own shares | |||||||||||
| Official market - legal basis | |||||||||||
| art. 56. 1. 2 of Act on Public Offering. | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| Sofia, Bulgaria, December 20, 2019 - Sopharma AD (3JR: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that on December 19, 2019 the Company bought 2 000 own shares representing 0.0015% of the share capital of the Company, at a total value of 6 890 BGN on the Bulgarian Stock Exchange, the average price per share was 3.4450 BGN. | |||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| Current report_99_buy back_espi.pdfCurrent report_99_buy back_espi.pdf | Notification for acquisition of own shares | ||||||||||
| SOPHARMA AD | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) |
||||||||||||
| 1220 | Sofia | ||||||||||||
| (post code) | (city) | ||||||||||||
| IlienskoShosse | 16 | ||||||||||||
| (street) | (number) | ||||||||||||
| +359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nd | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2019-12-20 | Ognian Donev | Executive Director | |||